UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): Monday, October 25, 2019

Generex biotechnology corpORATION

(Exact of registrant as specified in its charter)

 

DELAWARE 000-29169 98-0178636
State or other jurisdiction of incorporation   Commission File Number IRS Employer Identification №.

 

10102 USA Today Way, Miramar, Florida 33025

(Address of principal executive offices) (Zip Code)

 

(416) 364-2551

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ¨

 

 
 

 

Item 5.07 – Submission of matters to a vote of Security Holders

 

The annual meeting of Generex Biotechnology Corporation was held on Friday, October 25, 2019. The Proxy information has been furnished previously on EDGAR. Quorum was met and all of the nominated directors were elected, and our nominated independent accountant was ratified.

The tabulated results of the votes are as follows:

 

Proposal #1 - Election of Directors:

 

  For Withheld Broker Non-Votes
Joseph Moscato 32,038,316 82,175  
Dr. Craig Eagle 32,032,644 87,847  
Brian T. McGee 32,037,785 82,706  
James Anderson 32,031,375 89,116  
Lawrence Salvo 32,041,124 79,367  
Mark Prioletti 32,022,545 97,946  
Omar Gazouli 32,026,872 93,619  
      13,297,629

 

Proposal #2 - Ratifying Mazars as independent public accountant:

 

  For Against Abstain
Mazars USA, LLP 45,093,327 271,333 53,460

 

 

Proposal #3 – to Adjourn the meeting, if necessary, to solicit additional proxies

 

  For Against Abstain
To adjourn if necessary 44,989,549 382,527 46,044

 

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date: Monday, October 28, 2019

 

 

Generex Biotechnology Corp.

 

/s/Joe Moscato

By: Joe Moscato, CEO, President

Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Generex Biotechnology (CE) Charts.
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Generex Biotechnology (CE) Charts.